Sight Sciences 10-Q: Q3 Revenue $24.9M, Net Loss Narrows to $6.8M, Cash $77.4M
SGHT has more than doubled off its 52-week low of $3.378 on elevated volume (2.2× avg).
Summary
Sight Sciences' Q3 10-Q confirms $24.9M revenue (+25%) and a narrowed $6.8M net loss, with $77.4M of cash against $41.0M of debt and nine-month operating burn down to $15.1M from $27.9M.
Key Events · Earnings and Guidance · SGHT
-
Q3 Revenue Up 25% to $24.9M
Revenue rose to $24.9M from $19.9M a year ago, with Interventional Dry Eye jumping to $3.9M from $0.2M and Interventional Glaucoma up 6.7% to $21.0M.
-
Net Loss Narrows to $6.8M
Q3 net loss was $6.8M, or $(0.12) per share, versus $8.2M and $(0.16) a year ago; nine-month loss was $24.2M versus $34.3M.
-
Cash Burn Cut, Runway Extended
Nine-month operating cash use fell to $15.1M from $27.9M. Cash and equivalents stood at $77.4M at September 30, 2026 against $41.0M carrying value of Hercules term debt.
-
Hercules Interest-Only Period Extended
An October 2026 fourth amendment pushed the interest-only expiration from February 1, 2027 to August 1, 2027, moving $6.1M of debt back to long-term; maturity remains July 1, 2028.
Analysis · SGHT · Industrial Applications And Services
The headline Q3 beat and raised guidance already hit the tape via this morning's 8-K, so the incremental news here is the balance sheet and cash trajectory. Nine-month operating cash burn fell to $15.1M from $27.9M a year ago, and with $77.4M of cash against $41.0M of term debt the company has funded runway well past the next twelve months — the going-concern question that hangs over a loss-making medtech is off the table for now. The October amendment pushing the interest-only period to August 1, 2027 removes near-term principal payments. The open risk is the Alcon appeal: $55.4M of awarded damages plus a 10% ongoing royalty ride on the Federal Circuit outcome and one remaining patent reexamination.
How filings like this one have moved
In the 30 days to Nov 6, 2026, 35.2% of the 2649 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SGHT was trading at $9.43 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $533.3M. The 52-week trading range was $3.38 to $10.06. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.